Literature DB >> 3134231

Incidence and significance of Clostridium difficile in hospitalized cancer patients.

M Gérard1, N Defresne, D Daneau, P Van der Auwera, M Delmée, A M Bourguignon, F Meunier.   

Abstract

The aim of the study was to assess the incidence and clinical significance of Clostridium difficile in patients in our cancer center. Over a period of seven consecutive months, 557 stools samples obtained from 156 hospitalized cancer patients (37 leukemic patients receiving oral antimicrobial prophylaxis and 119 patients from whom a stool sample was sent to the laboratory) were analyzed for the presence of Clostridium difficile. Clostridium difficile and/or its toxin was recovered from 13 (35%) of the 37 patients receiving oral antimicrobial prophylaxis, and from 15 (12%) of the other 119 patients (p less than 0.05). Isolation of Clostridium difficile was associated with diarrhoea in 13 (46%) of 28 patients but specific treatment was initiated only in 7 (25%) of the 28 patients in whom Clostridium difficile was isolated. The wide distribution of the serotypes identified in our patients does not suggest an epidemic situation in our hospital.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134231     DOI: 10.1007/bf01963101

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  26 in total

1.  Probability theory in the use of diagnostic tests. An introduction to critical study of the literature.

Authors:  H C Sox
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

2.  The epidemiology of Clostridium difficile with use of a typing scheme: nosocomial acquisition and cross-infection among immunocompromised patients.

Authors:  S R Heard; S O'Farrell; D Holland; S Crook; M J Barnett; S Tabaqchali
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

3.  Relapsing pseudomembranous colitis associated with cancer chemotherapy.

Authors:  V Fainstein; G P Bodey; R Fekety
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

4.  Clostridium difficile and its toxin in healthy neonates.

Authors:  S A Richardson; P A Alcock; J Gray
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-24

5.  Identification of Clostridium difficile as a cause of pseudomembranous colitis.

Authors:  R H George; J M Symonds; F Dimock; J D Brown; Y Arabi; N Shinagawa; M R Keighley; J Alexander-Williams; D W Burdon
Journal:  Br Med J       Date:  1978-03-18

Review 6.  Epidemiology of Clostridium difficile-induced intestinal disease.

Authors:  M E Mulligan
Journal:  Rev Infect Dis       Date:  1984 Mar-Apr

7.  Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982.

Authors:  B Aronsson; R Möllby; C E Nord
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

8.  Pseudomembranous colitis in a leukaemia unit: a report of five fatal cases.

Authors:  D W Milligan; J K Kelly
Journal:  J Clin Pathol       Date:  1979-12       Impact factor: 3.411

9.  Typing scheme for Clostridium difficile: its application in clinical and epidemiological studies.

Authors:  S Tabaqchali; D Holland; S O'Farrell; R Silman
Journal:  Lancet       Date:  1984-04-28       Impact factor: 79.321

10.  Detection of Clostridium difficile in faeces by direct gas liquid chromatography.

Authors:  P N Levett
Journal:  J Clin Pathol       Date:  1984-02       Impact factor: 3.411

View more
  3 in total

Review 1.  Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations.

Authors:  F de Lalla
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

Review 2.  Polymicrobial septicemia with Clostridium difficile in acute diverticulitis.

Authors:  M Gérard; N Defresne; P Van der Auwera; F Meunier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

3.  How do hospital professionals involved in a randomised controlled trial perceive the value of genotyping vs. PCR-ribotyping for control of hospital acquired C. difficile infections?

Authors:  Ala Szczepura; Susan Manzoor; Katherine Hardy; Nigel Stallard; Helen Parsons; Savita Gossain; Peter M Hawkey
Journal:  BMC Infect Dis       Date:  2014-03-21       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.